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admission to an intensive-care unit or 
intubation) might be difficult.
The European Academy of Neurology 
(EAN) aims to gather evidence about 
the neurological impact of COVID-19. 
Encompassing 45 000 European 
neurologists, 47 European National 
Neurological Societies, and ten associate 
National Societies from Africa and Asia, 
the EAN has created a multidisciplinary 
task force, the EANcore COVID-19, to 
develop: diagnostic and treatment 
recommendations for patients with 
COVID-19 with all subgroups of 
neurological condition; an online Neuro 
COVID-19 survey on neurological 
complications of COVID-19 (for which 
more than 4200 responses have been 
already received as of April 30, 2020); 
and the EAN Neuro COVID-19 registry, 
which arises from a collaboration with 
the Italian, Spanish, and Portuguese 
neuro logical societies and aims to 
collect stand ardised information about 
demographics, comorbidities, general 
and neurological manifestations, and 
course and outcome of COVID-19. This 
registry, launched on April 29, 2020, will 
be offered by the EAN to all interested 
neurologists, neurology departments, 
and National Societies, together with 
the necessary ethical, methodological, 
and technical support. EAN will also 
provide a platform  for rapid COVID-19-
related literature alerts and information.
Difficult times ask for innovative and 
courageous solutions. Neurologists 
are called on to play their part. The 
EAN is ready to support and join 
inter na tional efforts to alleviate the 
medi cal consequences and also the 
burden associated with the COVID-19 
pandemic.
All authors declare no competing interests.
Elena Moro, Gunther Deuschl, 
Marianne de Visser, Dafin Muresanu, 
Riccardo Soffietti, Anthony Marson, 
Marie Vidailhet, David B Vodusek, 
*Claudio L A Bassetti
claudio.bassetti@insel.ch
Division of Neurology, CHU de Grenoble, Grenoble 
Alpes University, Grenoble, France (EM); Klinik für 
Neurologie, Universitätsklinikum Schleswig-Holstein, 
Campus Kiel, Kiel, Germany (GD); Department of 
to make the raw consolidated data 
from this web-based case report form 
open access. 
MPS reports personal fees from Biogen, Merck, Teva, 
Novartis, Sanofi Genzyme, Roche, GeNeuro, and 
Medday, outside the submitted work. The Italian 
Study Group on COVID-19 infection in multiple 
sclerosis thanks Roche for donating the web-based 
platform for data collection. The study was approved 
by the Regional Ethics Committee of Liguria 
(n 130/2020 – DB id 10433). There is no prominent 
authorship and MPS is acting as the corresponding 
author on behalf of the Italian Study Group on 
COVID-19 infection in multiple sclerosis.
Maria Pia Sormani, on behalf of the 
Italian Study Group on COVID-19 
infection in multiple sclerosis
mariapia.sormani@unige.it
Department of Health Sciences, University of Genoa, 
Genova 16132, Italy; and IRCCS Policlinico San 
Martino Hospital, Genoa, Italy
1 Li C, Romagnani P, von Brunn A, 
Hans-Joachim A. SARS-CoV-2 and Europe: 
timing of containment measures for outbreak 
control. Infection 2020; published online 
April 9. DOI:10.1007/s15010-020-01420-9.
2 Chinese Center for Disease Control and 
Prevention. The epidemiological 
characteristics of an outbreak of 2019 novel 
coronavirus diseases (COVID-19) in China. 
Zhonghua Liu Xing Bing Xue Za Zhi 2020; 
41: 145–51.
3 Multiple Sclerosis International Federation. 
Global COVID-19 advice for people with MS. 
March, 2020. http://www.msif.org/wp-
content/uploads/2020/03/MSIF-Global-
advice-on-COVID-19-for-people-with-MS.
docx-1.pdf (accessed April 23, 2020).
A call from the European 
Academy of Neurology 
on COVID-19 
The frequency, determinants, and 
evolution of neurological manifesta-
tions associated with coronavirus 
disease 2019 (COVID-19) remain 
unknown, because of few available data 
and the retrospective nature of most 
reports.1–4 Furthermore, the possible 
neuro tropic nature of the virus (leading 
to dyspnoea and respiratory failure) is 
yet to be confirmed.5
Neurologists are facing many other 
challenges in the current pandemic, 
including the management of older 
patients and those with pre-existing 
neurological disorders for whom ethical 
decisions about escalation of care (eg, 
For EAN survey on neurological 
symptoms in patients 
with COVID-19 see 
https://www.surveymonkey.
com/r/eansurvey_lancet
For more information on how to 
express interest in the registry 
see https://forms.gle/
xBbrwcjRTxvQnuzj7 A call for a global 
COVID-19 Neuro 
Research Coalition
Reports are emerging at a rapid pace 
that the severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2) 
affects the nervous system in various 
ways. Preliminary data from Wuhan, 
China, suggest that neurological 
manifesta tions are present in more 
than 30% of patients presenting with 
coronavirus disease 2019 (COVID-19).1 
Neurological features range from 
quite diffuse neurological signs and 
symptoms like headache, dizziness, 
reduced level of consciousness, con-
fusion, diffuse corticospinal tract signs, 
and paraesthesia, to more specific 
mani festations, such as seizures, stroke, 
encephalitis, or meningoencephalitis, 
and myopathy.1,2 To date, SARS-CoV-2 
has not been detected in the neural 
For the EANcore COVID-19 
website see https://www.ean.
org/ean/eancore-covid-19
Correspondence
www.thelancet.com/neurology   Vol 19   June 2020 483
asymptomatic. Asymptomatic child-
ren might still harbour the virus, 
with so far unknown effects on their 
health status later in life, including 
brain development. Additionally, 
once a vaccine becomes available, 
careful monitoring across age groups 
and disease spectra will be required 
to identify adverse effects and any 
deterioration of signs and symptoms 
in patients with neurological diseases. 
Overall, understanding is needed of 
whether susceptible groups exist who 
are at increased risk of deterioration 
after SARS-CoV-2 infection, how to 
detect them by use of biomarkers, 
and whether treatment needs to 
be specifically targeted in case of 
neurological signs and symptoms. 
Systems for clinical surveillance, 
epidemiological and clinical research, 
and post-mortem studies will be 
needed to achieve this aim.
The COVID-19 pandemic necessitates 
close collaboration on a global scale, 
with a special emphasis on inclusion 
of colleagues and partner institutions 
from low-income and middle-income 
countries. Inspired by the COVID-19 
Clinical Research Coalition described 
recently in The Lancet,5 our proposal is to 
build on and link existing international 
neurology partnerships, such as the 
Brain Infections Global COVID-Neuro 
Network, that provides a network for 
interested clinicians, a daily update of 
all publications relating to neurological 
COVID-19 disease, and freely accessible 
downloads of case-record forms; the 
European Academy of Neurology 
COVID-19 registry; the Lean European 
Open Survey on SARS-CoV-2 Infected 
Patients endorsed by the German 
Neurological Society; and the activities 
of the World Federation of Neurology 
around COVID-19. Additionally, WHO 
can play an important part in building 
this coalition through identifying 
priorities and developing harmonised 
systems for neurological research. 
We are therefore launching a call for 
an inclusive and collaborative global 
COVID-19 Neuro Research Coalition co-
created by the research communities 
around the world (panel). In a first 
step, we will create a platform of 
exchange and communication. If you 
are interested in becoming part of 
this community, please register at the 
Center for Global Health, Department 
of Neurology, Technical University of 
Munich, Germany, by sending an email 
to covid19.neuro@med.tum.de.
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tissue directly, although it has been 
isolated from the CSF of some patients.3 
The hypothesis of neurotropism with 
subsequent neuronal injury, either 
directly or indirectly (through immune 
mechanisms), is supported by previous 
findings from other infections with 
severe acute respiratory syn drome 
CoV and Middle East respiratory 
syndrome CoV.3
Pre-existing cardiovascular or 
pulmonary disease and old age increase 
the chances of contracting SARS-CoV-2 
infection and those risk factors are often 
present in patients with neurological 
disorders. Individuals with autoimmune 
diseases, such as multiple sclerosis, who 
require immunotherapy, might be at 
increased risk of SARS-CoV-2 infection 
and neurologists are in need of tailored 
recommendations for immunotherapy, 
relapse management, and delivery 
of care. Patients with Parkinson’s 
disease have an increased risk for 
cardiovascular complications and can 
have multiple comorbidities, including 
cognitive impairment, depression, 
and psychosis, which can deteriorate 
during isolation.4 Also, many patients 
with cognitive impairment might not 
be able to follow infection preven-
tion and control recommendations, 
thereby putting themselves and their 
caregivers at risk of contracting SARS-
CoV-2. Additionally, very little is known 
about potential interaction between 
various medications for chronic neuro-
logical diseases and drug treatment 
for COVID-19. 
Because the effects of SARS-CoV-2 
on the nervous system are largely 
unknown, estimating the neurological 
morbidity that might occur from the 
acute phase of the pandemic is difficult. 
Also, whether patients might have 
long-term neurological or cognitive 
sequelae, or whether pre-existing 
neuro logical disease might deteriorate 
(eg, patients with mild cognitive 
impairment might have little cognitive 
reserve and develop dementia early) 
is unknown. Effects of coronavirus in 
children seem less severe and often 
the virus is present but children are 
Panel: Potential aims for a global COVID-19 Neuro Research Coalition
• To create a platform for global scientific exchange and networking
• To collaborate and partner with our colleagues in low-income and middle-income 
countries 
• To harmonise methods and research tools 
• To design joint studies, mobilise research funds, and publish together
• To establish, if appropriate, and to collaborate with existing registries 
• To pursue new research translation into policies 
• To join forces with national neurological research societies, the European, 
African, and American Academies of Neurology, the International Child 
Neurology Association, and the World Federation of Neurology
• To collaborate in a multidisciplinary way with other medical and allied disciplines 
and their respective societies and networks
• To team up with the brain health unit and COVID-19-related activities of the WHO
• To pursue in all activities a One Health, gender-based and equity-based approach, 
promoting the vision of Universal Health Coverage and the aims of the 
Sustainable Development Goals 
COVID-19=coronavirus disease 2019.
For the Brain Infections Global 
COVID-Neuro Network see 
www.brain 
infectionsglobal.tghn.org/covid-
neurology-resource/
For the COVID-19-related 
resource base of the European 
Academy of Neurology see 
www.ean.org/ean/eancore-
covid-19
For more on the Lean European 
Open Survey on SARS-CoV-2 
Infected Patients see 
https://leoss.net
For more on the COVID-19 
related resource base of the 
World Federation of Neurology 
see https://wfneurology.org/
covid-19-and-world-neurology
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reported on 214 patients who were 
admitted to hospital in Wuhan, China, 
with acute COVID-19. Symptoms were 
severe in 59% (mean age 58·7 years) 
of these patients, and non-severe 
in 41% (mean age 49·9 years). In 
total, 78 (36%) of 214 patients had 
neurological compromise, which was 
more common in severe (46%) than in 
non-severe (30%) cases and included 
stroke, impaired consciousness, myop-
athy, and neu ralgic pain. Viral menin-
go encephalitis with presence of 
SARS-CoV-2 in CSF by viral genome 
sequencing has been reported in 
patients in China3 and Japan.4 In 
the USA, a woman aged between 
50 and 60 years developed COVID-19 
and altered mental status. Brain 
MRI on this patient showed bilateral 
haemorrhagic rim-enhancing lesions 
within thalami, medial tem poral lobes, 
and subinsular regions char acteristic 
of acute haemorrhagic necrotis ing 
encephalopathy.5 This con dition also, 
but rarely, occurs in influenza and other 
encephali tides in association with 
cytokine storm syndrome.
Amid confronting a severe out break 
of COVID-19, the Spanish Neurological 
Society (Sociedad Española de 
Neurología) implemented a registry 
of neuro logical manifestations in 
patients with confirmed COVID-19. 
We applaud this initiative and propose 
to expand these efforts globally to 
define the nervous system involve-
ment in COVID-19. The Environmental 
Neurology Specialty Group of the World 
Federation of Neurology (ENSG-WFN) 
is encouraging neurological soci eties 
around the world to develop national 
or regional neuroepidemiological 
data banks to report all cases of 
new-onset, acute, delayed, and any 
long-latency neurological disorders 
associ ated with SARS-CoV-2 infection 
during the COVID-19 pandemic. 
Late parkinsonism occurred among 
survivors of the 1918–20 influenza 
pandemic. Therefore, neurologists 
must be prepared for the occurrence 
of delayed neurological manifestations 
of COVID-19.
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COVID-19 international 
neurological registries 
The pandemic of coronavirus disease 
2019 (COVID-19) due to severe acute 
respiratory syndrome coronavirus 2 
(SARS-CoV-2) has already affected 
more than 2·7 million people and 
caused more than 192 000 deaths 
worldwide. Respiratory symptoms are 
the most common, and neurogenic 
breathing failure is suspected to be 
involved.1 Symptoms such as anosmia, 
dysgeusia, headache, and muscle pain 
have been noted, along with reports of 
central and peri pheral nervous system 
involvement. Mao and colleagues2 
For the Spanish Neurological 
Society registry see 
http://www.sen.es/covid-19
